Safety, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects of Oral NEO6860, a Modality Selective TRPV1 Antagonist

Most previous TRPV1 antagonist programs have been put on hold, mainly due on-target adverse events: hyperthermia and impaired noxious heat sensation. NEO6860 is a TRPV1 antagonist, blocking capsaicin activation of the target, with little or no effect against pH or heat activation. The hypothesis is that this pharmacological profile will translate into analgesia without undesired effects on the body temperature or heat-pain threshold.This phase I, double blind, placebo controlled, ascending dose study, included 64 subjects.

from The Journal of Pain http://ift.tt/2kQjER5
via IFTTT